Southern, your posts clearly indicate knowledge and experience with biotechs, and are infinitely more informative than what I can offer. I strongly believe you are underestimating the Clinuvel team and the strategy they have layed out. The meticulous (to the point of nauseam) nature of their trials and analysis will pave the way to approval with the EMA. The timing of this will avoid dilution. The approval itself will simply crack the door on the availability of this drug, which Phillipe & co. will kick in with expediated Vitiligo trials, introduction of 9900 and pediatric trials and the inevitable off label use. All of this will lead to a multibillion dollar company in 3 years or so. Use charts and your experience if you like, but timing this game is foolish. The odds of making 20 times your money by 2016 are no better any where else, so wait and be rewarded.
CUV Price at posting:
$1.95 Sentiment: LT Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)